Thursday 7 May, 2026
Objectives Bictegravir is a second-generation human immunodeficiency virus (HIV) integrase strand transfer inhibitor (INSTI) widely used in first-line antiretroviral therapy[1]….
Read moreAbstracts
Model-informed approach to Support Dose Selection for Lurbinectedin in Pediatric Patients with Advanced Solid Tumors and Recurrent/Refractory Ewing Sarcoma
Thursday 7 May, 2026
Introduction Lurbinectedin is a selective inhibitor of oncogenic transcription that has demonstrated significant clinical activity across various adult solid tumors….
Read moreTOWARD AUTONOMOUS PHARMACOMETRICS: A MULTI AGENT FRAMEWORK FOR STRUCTURE DISCOVERY, COVARIATE SELECTION AND GRAY-BOX MODELING
Thursday 7 May, 2026
Objectives: Developing population pharmacokinetic (PopPK) models is an iterative, expert-dependent process. We present an autonomous multi-agent framework capable of performing…
Read moreMechanistic PK/PD Modeling Framework for Targeted Covalent Inhibitors: Applications to Guide Lead Optimization, Inform Study Design, and Predict in vivo Efficacy
Thursday 7 May, 2026
Introduction Targeted covalent inhibitors (TCIs) are a therapeutic modality which currently attracts much attention, especially in oncology drug discovery and…
Read moreNo One-Size-Fits-All: A Multi-Model Evaluation of Optimization-Based and Surrogate-Assisted Virtual Population Generation in QSP
Thursday 7 May, 2026
Background Quantitative systems pharmacology (QSP) models increasingly support clinical decision-making by integrating mechanistic knowledge with heterogeneous experimental data. Sparse population-level…
Read moreA Generative AI approach for reconstructing synthetic data cohorts for MBMA.
Thursday 7 May, 2026
1. INTRODUCTION Pharmacokinetics-Pharmacodynamics (PK/PD) data analysis is a cornerstone of both drug development and efficacy and safety studies. However, individual-level…
Read morenmbench: An Integrated Text-Editor–Based Environment for NONMEM Population Modeling and Simulation
Thursday 7 May, 2026
Objectives: NONMEM remains the gold standard for population pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation. Despite its analytical robustness, routine modeling workflows…
Read moreA multi-compartment QSP model of hepatitis B infection linking viral life cycle and immune regulation to support model-informed therapy evaluation
Thursday 7 May, 2026
Objectives: Chronic hepatitis B (CHB) remains a major global health burden, and functional cure (sustained HBsAg loss off therapy) is…
Read moreQuantifying the CYP3A ontogeny in the gut wall and liver using a reduced population physiologically-based pharmacokinetic model
Thursday 7 May, 2026
Objectives: While the ontogeny of CYP3A enzymes and the difference between gut wall and hepatic maturation have been extensively studied,…
Read moreCOMPARISON OF MACHINE LEARNING ALGORITHMS FOR RAPID COMPARTMENTAL MDOEL SELECTION
Thursday 7 May, 2026
Introduction: Automated pharmacokinetic (PK) model building has been explored since 2006, when Bies et al. proposed using a Genetic Algorithm…
Read more